Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Splanchnic

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    18 result(s) found for: Splanchnic. Displaying page 1 of 1.
    EudraCT Number: 2017-000071-90 Sponsor Protocol Number: AGO/2017/002 Start Date*: 2017-03-15
    Sponsor Name:Ghent University Hospital
    Full Title: Effect of sevoflurane and propofol on hepato-splanchnic pressure and flow during hepatobiliary surgery.
    Medical condition: patients scheduled for hepato-biliary surgery.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2012-002253-30 Sponsor Protocol Number: SVT-RUXO#2012 Start Date*: 2012-10-04
    Sponsor Name:UNIVERSITA' DEGLI STUDI DI FIRENZE
    Full Title: A phase 2 study of Ruxolitinib in patients with splanchnic vein thrombosis associated with myeloproliferative neoplasm
    Medical condition: splanchnic vein thrombosis associated with myeloproliferative neoplasm
    Disease: Version SOC Term Classification Code Term Level
    15.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10013238 Disorder myeloproliferative LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-002036-14 Sponsor Protocol Number: V3.10.5.2014 Start Date*: 2014-08-08
    Sponsor Name:Lars Bo Svendsen
    Full Title: The effect of epidural anaesthesia on systemic and splanchnic hemodynamic during gastroesophageal resections, a randomized controlled trial
    Medical condition: The effect of epidural anaesthesia on systemic and splanchnic hemodynamic during gastroesophageal cancer resection
    Disease: Version SOC Term Classification Code Term Level
    17.0 100000004864 10066354 Adenocarcinoma of the gastroesophageal junction LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2004-004384-29 Sponsor Protocol Number: Levosepsis1 Start Date*: 2005-05-23
    Sponsor Name:Dr GED DEMPSEY, University Hospital Aintree
    Full Title: Double blind randomised controlled trial of Levosimendan versus Dopexamine in septic shock
    Medical condition: Septic Shock
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-000818-78 Sponsor Protocol Number: 7-010-MR Start Date*: 2008-09-25
    Sponsor Name:POLICLINICO SAN DONATO IRCSS
    Full Title: Efficacy of fenoldopam mesilate in controlling splanchnic ischemia during cardiopulmonary bypass
    Medical condition: Patients to be submitted to cardiac surgery with expected prolonged CPB time
    Disease: Version SOC Term Classification Code Term Level
    9.1 10048935 Open heart surgery LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2015-004412-38 Sponsor Protocol Number: 1160.248 Start Date*: 2017-01-09
    Sponsor Name:Unilfarma - União Internacional de Lab. Farmacêuticos, Lda
    Full Title: RE-SPECT CVT: a randomised, open-label, exploratory trial with blinded endpoint adjudication (PROBE), comparing efficacy and safety of oral dabigatran etexilate versus oral warfarin in patients wit...
    Medical condition: cerebral vein and dural sinus thrombosis
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10008209 Cerebrovascular venous and sinus thrombosis HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) NL (Completed) ES (Completed) DE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-005162-29 Sponsor Protocol Number: RivaSVT100 Start Date*: Information not available in EudraCT
    Sponsor Name:A.O. OSPEDALE DI CIRCOLO E FONDAZIONE MACCHI
    Full Title: Treatment of portal, mesenteric, and splenic vein thrombosis with rivaroxaban. A pilot, prospective cohort study
    Medical condition: Portal, mesenteric, and splenic vein thrombosis
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004866 10043642 Thrombosis venous deep LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-003093-40 Sponsor Protocol Number: FADOI_032016 Start Date*: 2017-03-10
    Sponsor Name:FONDAZIONE FADOI
    Full Title: Apixaban for the treatment of venous thromboembolism in patients with cancer: a prospective randomized open blinded end point (PROBE) study- the CARAVAGGIO study.
    Medical condition: Venous thromboembolism in cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) BE (Completed) GB (GB - no longer in EU/EEA) DE (Completed) ES (Completed) PT (Completed) PL (Completed) NL (Completed) IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-002890-71 Sponsor Protocol Number: RifaxNK150612 Start Date*: 2012-08-16
    Sponsor Name:Flemming Bendtsen
    Full Title: Intestinal decontamination with rifaximin. Effects on the inflammatory and circulatory state in patients with cirrhosis and ascites - A randomised controlled clinical study
    Medical condition: Liver cirrhosis of any etilogy, complicated by decompensation and classified as Child-Pugh B or C
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004871 10024667 Liver cirrhosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2018-000833-12 Sponsor Protocol Number: POLYCHEM Start Date*: Information not available in EudraCT
    Sponsor Name:Azienda Ospedaliero-Universitaria di Parma
    Full Title: A prospective, randomized, parallel-group, adaptive design phase IIb/III, multicenter study, to assess the efficacy of polychemotherapy for inducing remission of newly diagnosed type 2 diabetes.
    Medical condition: type 2 diabetes mellitus
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-019500-23 Sponsor Protocol Number: MPD-RC111 Start Date*: 2012-02-15
    Sponsor Name:CONSORZIO MARIO NEGRI SUD
    Full Title: Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk Polycythemia Vera or High Risk Essential Thrombocythemia who are Either Hydroxyurea Resistant or Intolerant ...
    Medical condition: High risk polycythemia vera and high risk essential thrombocythemia
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10036057 Polycythaemia vera PT
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10015493 Essential thrombocythaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-001230-18 Sponsor Protocol Number: PRO-001 Start Date*: 2019-01-30
    Sponsor Name:Hellenic Genito-Urinary Cancer Group (HGUCG)
    Full Title: Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients. A prospective, randomised, international multicentre, open-label, blinded-endpoint Phase III study. PRO...
    Medical condition: Long-term thromboprophylaxis with tinzaparin in high-risk prostate or breast cancer patients.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004865 10049909 Venous thromboembolism prophylaxis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2007-006694-91 Sponsor Protocol Number: FARM6YNXAN Start Date*: 2008-05-23
    Sponsor Name:G.I.M.E.M.A.
    Full Title: A large-scale trial testing the intensity of CYTOreductive therapy to prevent cardiovascular events In patients with Polycythemia Vera (PV) – CYTO-PV.
    Medical condition: Polycytemia vera
    Disease: Version SOC Term Classification Code Term Level
    9.1 10028576 Myeloproliferative disorder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-002298-25 Sponsor Protocol Number: 20203331 Start Date*: 2021-09-15
    Sponsor Name:Fundación para la Investigación Biomédica del Hospital Universitario La Paz (FIBHULP)
    Full Title: A multicenter, adaptive, prospective, randomized trial evaluating the efficacy and safety of antithrombotic strategies in patients with COVID-19 following hospital discharge
    Medical condition: COVID-19
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-001709-21 Sponsor Protocol Number: 2020PI073 Start Date*: 2020-04-29
    Sponsor Name:CHRU de Nancy
    Full Title: Effectiveness of low molecular weight heparin at increased doses prophylaxis weight-adjusted, compared with lower doses prophylaxis (intermediate or standard), on the onset of venous thromboembolis...
    Medical condition: Prevention of thromboembolic events in hospitalised COVID-19 infected patients
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10014523 Embolism and thrombosis HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2014-002606-20 Sponsor Protocol Number: CV185-325/B0661037 Start Date*: 2015-11-06
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A RANDOMIZED, OPEN-LABEL, ACTIVE CONTROLLED, SAFETY AND DESCRIPTIVE EFFICACY STUDY IN PEDIATRIC SUBJECTS REQUIRING ANTICOAGULATION FOR THE TREATMENT OF A VENOUS THROMBOEMBOLIC EVENT
    Medical condition: Venous Thromboembolism
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10043565 Thromboembolic event LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) Outside EU/EEA AT (Completed) GB (GB - no longer in EU/EEA) ES (Ongoing) PT (Completed) IT (Not Authorised) FR (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-005624-10 Sponsor Protocol Number: OVID-trial Start Date*: 2021-05-06
    Sponsor Name:University Hospital Zurich
    Full Title: ENOXAPARIN FOR PRIMARY THROMBOPROPHYLAXIS IN AMBULATORY PATIENTS WITH CORONAVIRUS: THE MULTICENTER RANDOMIZED CONTROLLED OVID TRIAL
    Medical condition: Patients diagnosed with COVID-19, a novel viral disease characterized by severe systemic, pulmonary, and vessel inflammation and coagulation activation.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    22.1 10021881 - Infections and infestations 10061229 Lung infection LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-005530-42 Sponsor Protocol Number: imPaCT-PRO-01 Start Date*: 2021-12-07
    Sponsor Name:Institute of Molecular Medicine and Biomedical Research (IMBE)
    Full Title: The impact of Thromboprophylaxis on Progression Free Survival of Patients with Advanced Pancreatic Cancer. The Pancreatic Cancer & Tinzaparin Prospective (imPaCT-PRO) study
    Medical condition: Thromboprophylaxis in patients with advanced pancreatic cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10043607 Thrombosis PT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10068067 Tumour thrombosis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Fri May 02 07:32:47 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA